@entity2682 has been reported to be effective for essential @entity400 (ET) based on open-label trials. We studied @entity2682 (1800 mg/day) and placebo in a double-blind crossover design in 20 ET @entity1 . Eighteen @entity1 completed the study and two @entity1 dropped out as a result of adverse effects which resolved when the medication was discontinued. @entity400 was assessed at baseline and after 2 weeks of @entity2682 and placebo treatment. One @entity1 was mildly improved and another was moderately improved with placebo. Similarly, one @entity1 reported mild improvement and another @entity1 had marked improvement with @entity2682 . All the remaining @entity1 either reported no change or were worse with both treatment arms. There was no significant difference for total @entity400 score, hand @entity400 score, handwriting scores, or pouring scores. Sickness Impact Profile scores were no different between placebo and @entity2682 . Our results suggest that as an adjuvant therapy in ET, @entity2682 has limited benefit.

Double-blind controlled trial of XXXX in essential @entity400 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor', 'Tremor'] @entity2682 :: ('MESH:C040029', 'Chemical') :: ['Gabapentin', 'gabapentin']
@entity2682 :: (MESH:C040029,Chemical) :: ['gabapentin']
